| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
RP5063 targets multiple serotonin (5-HT) receptors, including 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors, with varying affinity and functional activity (partial agonism or antagonism). This multimodal profile may contribute to its therapeutic effects in schizophrenia and pulmonary arterial hypertension by modulating serotonin signaling across multiple pathways.
|
|---|---|
| ln Vitro |
In cell-based functional assays, RP5063 shows activity at multiple 5-HT receptors. It acts as a partial agonist at 5-HT1A and 5-HT2A receptors, an antagonist at 5-HT2B, and shows activity at 5-HT6 and 5-HT7 receptors. The compound also modulates dopamine and norepinephrine systems indirectly through serotonin receptor interactions. It has been studied for its antipsychotic and vasodilatory properties in vitro.
|
| ln Vivo |
In animal models, RP5063 has been studied for antipsychotic-like effects (e.g., PCP- or amphetamine-induced hyperlocomotion, prepulse inhibition deficits) and for its effects in models of pulmonary arterial hypertension (reducing pulmonary artery pressure and vascular remodeling). It shows a favorable profile with low extrapyramidal side effect liability and may improve cognitive function and negative symptoms in addition to positive symptoms of schizophrenia.
|
| Enzyme Assay |
Serotonin receptor binding is assessed using membrane preparations from cells expressing recombinant human 5-HT receptors. Membranes are incubated with appropriate radioligands ([³H]-8-OH-DPAT for 5-HT1A, [³H]-ketanserin for 5-HT2A, [³H]-LSD for 5-HT2B, [³H]-mesulergine for 5-HT2C, [³H]-LSD for 5-HT6, [³H]-LSD for 5-HT7) and varying concentrations of RP5063 (0.01-1000 nM) in binding buffer (50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl₂ and 0.1% BSA) for 60-90 minutes at 25-37°C. Nonspecific binding is determined with appropriate displacers (e.g., 10 µM serotonin, 10 µM ketanserin). Bound radioactivity is collected on filters and counted. Ki values are calculated. Functional activity (agonist/antagonist) is assessed by GTPγS binding or cAMP accumulation assays.
|
| Cell Assay |
Cells expressing recombinant human 5-HT receptors (e.g., CHO or HEK293 cells) are treated with RP5063 (0.01-1000 nM) for 30-60 minutes. Receptor activation is measured by GTPγS binding, cAMP accumulation (for Gαi- or Gαs-coupled receptors), or calcium mobilization (Fluo-4 AM for Gαq-coupled receptors). Antagonist activity is determined by pre-incubation with RP5063 followed by stimulation with the reference agonist (e.g., serotonin). For antiproliferative effects, pulmonary artery smooth muscle cells are treated with RP5063 (0.1-100 µM) for 24-72 hours, and proliferation is measured by BrdU incorporation or MTT assay.
|
| Animal Protocol |
For schizophrenia models, mice or rats are administered RP5063 (0.1-10 mg/kg, i.p. or p.o.) 30-60 minutes before behavioral testing. PCP- or amphetamine-induced hyperlocomotion is measured in open field tests. Prepulse inhibition of the acoustic startle response is assessed. For pulmonary arterial hypertension, monocrotaline- or hypoxia-induced PAH models are used. RP5063 is administered orally at 1-30 mg/kg daily for 2-4 weeks. Right ventricular systolic pressure is measured by catheterization. Pulmonary artery remodeling is assessed by histomorphometry. Brain or lung tissues are collected for receptor occupancy studies and biochemical analysis.
|
| References |
Sci Rep. 2018 May 2;8(1):6892.
|
| Molecular Formula |
C22H26CL3N3O3
|
|---|---|
| Molecular Weight |
486.819142818451
|
| Exact Mass |
485.103
|
| CAS # |
1708960-04-6
|
| PubChem CID |
46864308
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=CC=CC=1N1CCN(CCCCOC2=CC=C3C(=C2)NC(CO3)=O)CC1)Cl.Cl
|
| InChi Key |
GMTQOJSRMVAFIF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25Cl2N3O3.ClH/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)1H
|
| Chemical Name |
6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one hydrochloride
|
| Synonyms |
RP-5063 Hydrochloride RP5063 HCl RP5063 Hydrochloride RP-5063 HClRP 5063 Hydrochloride RP 5063 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0541 mL | 10.2707 mL | 20.5415 mL | |
| 5 mM | 0.4108 mL | 2.0541 mL | 4.1083 mL | |
| 10 mM | 0.2054 mL | 1.0271 mL | 2.0541 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.